-
EP4106741
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4106741
| EP4106741 - USE OF A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR OR OF A COMBINATION OF A SGC STIMULATOR AND AN SGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF SGC IS OXIDIZED OR WHEREIN SGC IS DEFICIENT IN HEME [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 26.01.2024 Database last updated on 18.11.2024 | |
| Former | Request for examination was made Status updated on 25.11.2022 | ||
| Former | The international publication has been made Status updated on 27.08.2021 | ||
| Former | unknown Status updated on 10.03.2021 | Most recent event Tooltip | 15.05.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Universiteit Maastricht Minderbroedersberg 4-6 6211 LK Maastricht / NL | For all designated states Academisch ziekenhuis Maastricht P. Debyelaan 25 6229 HX Maastricht / NL | [2022/52] | Inventor(s) | 01 /
SCHMIDT, Harald Horst Heinz Wilhelm Elsa-Brändström-Straße 7 52070 Aachen / DE | 02 /
ELBATRIK, Mahmoud Hassan Mahmoud Burgemeester Raatstraat 5 6224 VS Maastricht / NL | 03 /
DAO, Thao-Vi Huswertstr. 14 60435 Frankfurt / DE | 04 /
CASAS GUIJARRO, Ana Isabel Scharnerweg 8d 6224 JG Maastricht / NL | 05 /
SARIDAKI, Theodora 52072 Aachen / DE | 06 /
PETRAINA, Alexandra 6211 RP, Maastricht / NL | [2022/52] | Representative(s) | Nederlandsch Octrooibureau P.O. Box 29720 2502 LS The Hague / NL | [2022/52] | Application number, filing date | 21709142.0 | 18.02.2021 | [2022/52] | WO2021NL50111 | Priority number, date | NL20202024965 | 21.02.2020 Original published format: NL 2024965 | [2022/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021167458 | Date: | 26.08.2021 | Language: | EN | [2021/34] | Type: | A1 Application with search report | No.: | EP4106741 | Date: | 28.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.08.2021 takes the place of the publication of the European patent application. | [2022/52] | Search report(s) | International search report - published on: | EP | 26.08.2021 | Classification | IPC: | A61K31/197, A61K31/416, A61K31/427, A61K31/4439, A61K31/506, A61K31/5377, A61K45/06, A61P9/00, A61K31/137 | [2022/52] | CPC: |
A61K31/506 (EP,US);
A61K31/137 (EP,US);
A61K31/197 (EP,US);
A61K31/416 (EP,US);
A61K31/427 (EP,US);
A61K31/4439 (EP,US);
| C-Set: |
A61K31/506, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/52] | Validation states | MA | 28.07.2022 | Title | German: | VERWENDUNG EINES LÖSLICHEN GUANYLATZYKLASESTIMULATORS (SGC) ODER EINER KOMBINATION AUS EINEM SGC-STIMULATOR UND EINEM SGC-AKTIVATOR FÜR ZUSTÄNDE, BEI DENEN DIE HÄMGRUPPE VON SGC OXIDIERT IST, ODER BEI DENEN SGC EINEN MANGEL AN HÄM AUFWEIST | [2022/52] | English: | USE OF A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR OR OF A COMBINATION OF A SGC STIMULATOR AND AN SGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF SGC IS OXIDIZED OR WHEREIN SGC IS DEFICIENT IN HEME | [2022/52] | French: | UTILISATION D'UN STIMULATEUR DE GUANYLATE CYCLASE SOLUBLE (SGC) OU D'UNE COMBINAISON D'UN STIMULATEUR DE SGC ET D'UN ACTIVATEUR DE SGC DANS DES CONDITIONS DANS LESQUELLES LE GROUPE HÈME DE SGC EST OXYDÉ OU SGC EST DÉFICIENT EN HÈME | [2022/52] | Entry into regional phase | 28.07.2022 | National basic fee paid | 28.07.2022 | Designation fee(s) paid | 28.07.2022 | Examination fee paid | Examination procedure | 20.12.2021 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 28.07.2022 | Examination requested [2022/52] | 28.07.2022 | Date on which the examining division has become responsible | 29.03.2023 | Amendment by applicant (claims and/or description) | 26.01.2024 | Despatch of a communication from the examining division (Time limit: M04) | 15.05.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 31.01.2023 | Renewal fee patent year 03 | 22.02.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2009138165 (BAYER SCHERING PHARMA AG [DE], et al); | [I]WO2017136309 (IRONWOOD PHARMACEUTICALS INC [US]); | [XI]WO2020014504 (CYCLERION THERAPEUTICS INC [US]); | by applicant | WO0006568 | WO0006569 | WO0119355 | WO0119776 | WO0119778 | WO0119780 | WO0183490 | WO0242301 | WO02070462 | WO02070510 | WO03095451 | WO2009032249 | WO2011147809 | WO2012004258 | WO2012028647 | WO2012059549 | WO2014144100 |